What is Pfizer's biopharma — expected restructuring cost?

Pfizer (PFE) reported biopharma — expected restructuring cost of $3.7B in Q1 2026.

How has Pfizer's biopharma — expected restructuring cost changed year-over-year?

Pfizer's biopharma — expected restructuring cost increased by 54.2% year-over-year, from $2.4B to $3.7B.

What does biopharma — expected restructuring cost mean?

Represents the estimated future financial obligations associated with planned organizational changes, such as facility closures or workforce reductions within the biopharmaceutical business unit. This metric helps investors gauge the potential impact of future efficiency initiatives on the segment's bottom line.

Pfizer PFE Biopharma — Expected restructuring cost

Similar metrics at other companies

ATRPharma — Restructuring initiatives

$5K-97.4%

TMOLaboratory Products and Biopharma Services — Restructuring and other costs

$33M—

ROKExpected Restructuring and Related Costs

$92M-5.2%

CPBCorporate — Restructuring and Related Cost, Expected Cost Allocation

20%-1.0pp

APTVIntelligent Systems — Restructuring and Related Cost, Expected Cost

$5M—

CPBMeals & Beverages — Restructuring and Related Cost, Expected Cost Allocation

54%-16.0pp

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:RestructuringAndRelatedCostExpectedCost1.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's biopharma — expected restructuring cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's biopharma — expected restructuring cost?: Pfizer (PFE) reported biopharma — expected restructuring cost of $3.7B in Q1 2026.
How has Pfizer's biopharma — expected restructuring cost changed year-over-year?: Pfizer's biopharma — expected restructuring cost increased by 54.2% year-over-year, from $2.4B to $3.7B.
What does biopharma — expected restructuring cost mean?: Represents the estimated future financial obligations associated with planned organizational changes, such as facility closures or workforce reductions within the biopharmaceutical business unit. This metric helps investors gauge the potential impact of future efficiency initiatives on the segment's bottom line.